MCID: GLL008
MIFTS: 63

Gilles De La Tourette Syndrome

Categories: Genetic diseases, Rare diseases, Mental diseases

Aliases & Classifications for Gilles De La Tourette Syndrome

MalaCards integrated aliases for Gilles De La Tourette Syndrome:

Name: Gilles De La Tourette Syndrome 54 12 24 25 71 14 69
Tourette Syndrome 54 12 50 24 25 51 29 13 52 41 3 42
Gilles De La Tourette's Syndrome 50 24 25
Tourette Disorder 50 24 25
Gts 25 71
Chronic Motor and Vocal Tic Disorder 25
Gilles De La Tourette's Disease 24
Motor-Verbal Tic Disorder 12
Tourette's Syndrome 50
Tourette's Disorder 24
Tourette's Disease 25
Guinon's Disease 12
Psychogenic Tics 12
Maladie De Tics 24
Td 25
Ts 25

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant

Miscellaneous:
male:female ratio 4:1
onset ages 2 to 14 years


HPO:

32
gilles de la tourette syndrome:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Gilles De La Tourette Syndrome

NIH Rare Diseases : 50 tourette syndrome is a complex neurological disorder that is characterized by repetitive, sudden, uncontrolled (involuntary) movements and sounds (vocalizations) called tics. tourette syndrome is named for georges gilles de la tourette, who first described this disorder in 1885. a variety of genetic and environmental factors likely play a role in causing tourette syndrome. a small number of people with tourette syndrome have been found to have mutations involving the slitrk1 gene. the syndrome is believed to be linked to problems in certain areas of the brain, and the chemical substances (dopamine, serotonin, and norepinephrine) that help nerve cells talk to one another. it is estimated that about 1% of the population has tourette syndrome. many people with very mild tics may not be aware of them and never seek medical help. tourette syndrome is four times as likely to occur in boys as in girls. although tourette syndrome can be a chronic condition with symptoms lasting a lifetime, most people with the condition experience their worst symptoms in their early teens, with improvement occurring in the late teens and continuing into adulthood. last updated: 3/6/2016

MalaCards based summary : Gilles De La Tourette Syndrome, also known as tourette syndrome, is related to schizophrenia and low gamma-gt familial intrahepatic cholestasis, and has symptoms including aggressive behavior, self-mutilation and obsessive-compulsive behavior. An important gene associated with Gilles De La Tourette Syndrome is SLITRK1 (SLIT And NTRK Like Family Member 1), and among its related pathways/superpathways are Circadian entrainment and Amphetamine addiction. The drugs Clonidine and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

UniProtKB/Swiss-Prot : 71 Gilles de la Tourette syndrome: Neurologic disorder manifested particularly by motor and vocal tics and associated with behavioral abnormalities.

MedlinePlus : 41 if you have tourette syndrome, you make unusual movements or sounds, called tics. you have little or no control over them. common tics are throat-clearing and blinking. you may repeat words, spin, or, rarely, blurt out swear words. tourette syndrome is a disorder of the nervous system. it often occurs with other problems, such as attention deficit hyperactivity disorder (adhd) obsessive-compulsive disorder (ocd) anxiety depression the cause of tourette syndrome is unknown. it is more common in boys than girls. the tics usually start in childhood and may be worst in the early teens. many people eventually outgrow them. no treatment is needed unless the tics interfere with everyday life. excitement or worry can make tics worse. calm, focused activities may make them better. medicines and talk therapy may also help. nih: national institute of neurological disorders and stroke

CDC : 3 Meet two families and hear about their experiences living with Attention-Deficit/Hyperactivity Disorder and Tourette Syndrome.

NINDS : 51 Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. The first symptoms of TS are almost always noticed in childhood.  Some of the more common tics include eye blinking and other vision irregularities, facial grimacing, shoulder shrugging, and head or shoulder jerking. Perhaps the most dramatic and disabling tics are those that result in self-harm such as punching oneself in the face, or vocal tics including coprolalia (uttering swear words) or echolalia (repeating the words or phrases of others).  Many with TS experience additional neurobehavioral problems including inattention, hyperactivity and impulsivity, and obsessive-compulsive symptoms such as intrusive thoughts/worries and repetitive behaviors.

Genetics Home Reference : 25 Tourette syndrome is a complex disorder characterized by repetitive, sudden, and involuntary movements or noises called tics. Tics usually appear in childhood, and their severity varies over time. In most cases, tics become milder and less frequent in late adolescence and adulthood.

OMIM : 54
Tourette syndrome is a neurobehavioral disorder manifest particularly by motor and vocal tics and associated with behavioral abnormalities. Tics are sudden, brief, intermittent, involuntary or semi-voluntary movements (motor tics) or sounds (phonic or vocal tics). They typically consist of simple, coordinated, repetitive movements, gestures, or utterances that mimic fragments of normal behavior. Motor tics may range from simple blinking, nose twitching, and head jerking to more complex throwing, hitting, or making rude gestures. Phonic tics include sniffling, throat clearing, blowing, coughing, echolalia, or coprolalia. Males are affected about 3 times more often than females, and onset usually occurs between 3 and 8 years of age. By age 18 years, more than half of affected individuals are free of tics, but they may persist into adulthood (review by Jankovic, 2001). (137580)

Disease Ontology : 12 A tic disorder that is characterized by multiple physical (motor) tics and at least one vocal (phonic) tic present for more than a year.

Wikipedia : 72 Tourette syndrome (TS or simply Tourette\'s) is a common neuropsychiatric disorder with onset in... more...

Related Diseases for Gilles De La Tourette Syndrome

Diseases related to Gilles De La Tourette Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 121)
id Related Disease Score Top Affiliating Genes
1 schizophrenia 29.5 BDNF CNTNAP2 COMT DBH DRD2 DRD4
2 low gamma-gt familial intrahepatic cholestasis 12.0
3 turner syndrome 11.6
4 glanzmann thrombasthenia 11.5
5 virus-associated trichodysplasia spinulosa 11.5
6 cholestasis, progressive familial intrahepatic 1 11.4
7 trichotillomania 11.3
8 mitochondrial dna depletion syndrome 7 11.1
9 trichostasis spinulosa 10.9
10 timothy syndrome 10.9
11 tuberous sclerosis-1 10.9
12 cholestasis, benign recurrent intrahepatic 10.8
13 kleefstra syndrome 10.8
14 pancreatic neuroendocrine tumor 10.8
15 hodgkin lymphoma 10.8
16 sclerotylosis 10.7
17 albinism, oculocutaneous, type ib 10.7
18 tsc2 angiomyolipomas, renal, modifier of 10.7
19 antisocial personality disorder 10.7 DRD2 DRD4 SLITRK1
20 pyromania 10.7 DRD2 DRD4 SLC6A3
21 c8 deficiency, type ii 10.7 COMT DRD2 DRD4
22 intracranial cavernous angioma 10.7 DRD2 SLC6A3
23 tongue disease 10.7 COMT DRD2 SLC6A3
24 rhinoscleroma 10.6 COMT DRD2
25 hyperglycemia 10.6 CNTNAP2 SLC6A3
26 trifunctional protein deficiency 10.6
27 leukocyte adhesion deficiency, type iii 10.6
28 myopathy, lactic acidosis, and sideroblastic anemia 1 10.6
29 perry syndrome 10.6
30 bile acid synthesis defect, congenital, 1 10.6
31 adenine phosphoribosyltransferase deficiency 10.6
32 hyperparathyroidism, neonatal 10.6
33 bile acid synthesis defect, congenital, 2 10.6
34 ritscher-schinzel syndrome 1 10.6
35 bladder hepatoid adenocarcinoma 10.6 DBH DRD2 SLC6A3
36 acute female pelvic peritonitis 10.6 DBH DRD2 SLC6A3
37 asperger syndrome 10.6 BTBD9 DRD2 SLC6A3
38 long qt syndrome-11 10.6 DBH DRD2 SGCE
39 placenta disease 10.6 DRD2 DRD4
40 simpson-golabi-behmel syndrome 10.6 CNTNAP2 DBH DRD2 SLC6A3
41 segmental dystonia 10.6 DRD2 DRD5 SGCE
42 ulcerative colitis 10.5 BDNF COMT DRD2
43 parietal foramina 3 10.5 DBH DRD2 SLC6A3
44 intracranial thrombosis 10.5 CNTNAP2 DRD2
45 cecal benign neoplasm 10.5 COMT DRD2 DRD4 SLC6A3
46 brain meningioma 10.5 BDNF COMT DRD2
47 ganglioneuroma 10.5 DRD2 SGCE SLC6A3
48 parkinsonism-dystonia, infantile 10.5 COMT DRD2 SLC6A3
49 tic disorder 10.5
50 obsessive-compulsive disorder 10.5

Graphical network of the top 20 diseases related to Gilles De La Tourette Syndrome:



Diseases related to Gilles De La Tourette Syndrome

Symptoms & Phenotypes for Gilles De La Tourette Syndrome

Symptoms via clinical synopsis from OMIM:

54

Neurologic- Central Nervous System:
aggressive behavior
obsessive-compulsive behavior
echolalia
sleep disturbance
coprolalia
more

Clinical features from OMIM:

137580

Human phenotypes related to Gilles De La Tourette Syndrome:

32 (show all 8)
id Description HPO Frequency HPO Source Accession
1 aggressive behavior 32 HP:0000718
2 self-mutilation 32 HP:0000742
3 obsessive-compulsive behavior 32 HP:0000722
4 attention deficit hyperactivity disorder 32 HP:0007018
5 echolalia 32 HP:0010529
6 sleep disturbance 32 HP:0002360
7 motor tics 32 HP:0100034
8 phonic tics 32 HP:0100035

UMLS symptoms related to Gilles De La Tourette Syndrome:


athetosis, back pain, headache, pain, sciatica, seizures, sleep disturbances, syncope, tremor, chronic pain, vertigo/dizziness, sleeplessness

MGI Mouse Phenotypes related to Gilles De La Tourette Syndrome:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.13 ADRA1A ADRA2A BDNF BTBD9 CNTNAP2 COMT
2 homeostasis/metabolism MP:0005376 9.93 ADRA1A ADRA2A BDNF BTBD9 COMT DBH
3 nervous system MP:0003631 9.8 DRD4 DRD5 HDC HMBS SGCE SLC6A3
4 taste/olfaction MP:0005394 8.92 BDNF CNTNAP2 DRD2 SLC6A3

Drugs & Therapeutics for Gilles De La Tourette Syndrome

Drugs for Gilles De La Tourette Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4 4205-90-7 2803
2
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
3
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
4 Piracetam Approved Phase 4 7491-74-9
5
Guanfacine Approved, Investigational Phase 4,Phase 3 29110-47-2 3519
6
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2 51-61-6, 62-31-7 681
7
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
8
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
9
Haloperidol Approved Phase 4 52-86-8 3559
10
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
11
Ondansetron Approved Phase 4 99614-02-5 4595
12
Galantamine Approved Phase 4 357-70-0 9651
13
Glutamic Acid Approved, Nutraceutical Phase 4 56-86-0 33032
14 Etiracetam Investigational Phase 4 33996-58-6
15 Adrenergic Agents Phase 4,Phase 3,Phase 2
16 Adrenergic Agonists Phase 4,Phase 3
17 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3
18 Adrenergic alpha-Agonists Phase 4,Phase 3
19 Analgesics Phase 4,Phase 3
20 Antihypertensive Agents Phase 4,Phase 3
21 Autonomic Agents Phase 4
22 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2
23 Peripheral Nervous System Agents Phase 4,Phase 3
24 Sympatholytics Phase 4
25 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Phase 2
26 Cholinergic Agents Phase 4
27 Anticonvulsants Phase 4,Phase 3,Phase 1,Phase 2
28 Excitatory Amino Acid Agonists Phase 4
29 Excitatory Amino Acid Antagonists Phase 4
30 Excitatory Amino Acids Phase 4
31 Neuroprotective Agents Phase 4,Phase 3
32 Protective Agents Phase 4,Phase 3,Phase 2
33 Antipsychotic Agents Phase 4,Phase 3,Phase 1,Phase 2
34 Psychotropic Drugs Phase 4,Phase 3,Phase 1,Phase 2
35 Tranquilizing Agents Phase 4,Phase 3,Phase 1,Phase 2
36 Nootropic Agents Phase 4
37 Anti-Anxiety Agents Phase 4
38 Antidepressive Agents Phase 4
39 Antidepressive Agents, Second-Generation Phase 4
40 Antiemetics Phase 4
41 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
42 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
43 Cytochrome P-450 Enzyme Inhibitors Phase 4
44 Dopamine Agents Phase 4,Phase 3,Phase 1,Phase 2
45 Dopamine Antagonists Phase 4,Phase 3,Phase 1,Phase 2
46 Gastrointestinal Agents Phase 4
47 Haloperidol decanoate Phase 4
48 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
49
Serotonin Phase 4,Phase 2 50-67-9 5202
50 Serotonin Agents Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 133)

id Name Status NCT ID Phase Drugs
1 Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD Unknown status NCT00152750 Phase 4 APO-clonidine
2 Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission Completed NCT01018056 Phase 4 D-serine;Riluzole;Placebo
3 Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT00241176 Phase 4 Aripiprazole
4 Comparison of Keppra and Clonidine in the Treatment of Tics Completed NCT00370838 Phase 4 Levetiracetam;Clonidine
5 Guanfacine in Children With Tic Disorders Completed NCT01547000 Phase 4 placebo;extended-release guanfacine (Intuniv)
6 Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
7 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
8 Safety Study of Galantamine in Tic Disorders Terminated NCT00226824 Phase 4 galantamine
9 Pallidal Stimulation and Gilles de la Tourette Syndrome Completed NCT00478842 Phase 3
10 Safety & Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01416441 Phase 3 aripiprazole
11 Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01418352 Phase 3 aripiprazole 52.5 mg;Matching Placebo;Aripiprazole 77.5 mg;Aripiprazole 110 mg
12 Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01418339 Phase 3 aripiprazole;Placebo
13 A Randomized, Placebo-Controlled, Tourette Syndrome Study. Completed NCT00206323 Phase 3 Topiramate (drug)
14 An Open-Label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome. Completed NCT00206336 Phase 3 Topiramate (drug)
15 Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727700 Phase 3 Aripiprazole;Placebo
16 Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727713 Phase 3 Aripiprazole
17 Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder Completed NCT00706589 Phase 3 aripiprazole;placebo
18 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder Completed NCT00004376 Phase 3 guanfacine
19 Cognitive Behavior Therapy and Habit Reversal Training for the Treatment of Chronic Tic Disorders in Children Completed NCT00218777 Phase 2, Phase 3
20 Phase III Study of 5LGr to Treat Tic Disorder Completed NCT01501695 Phase 3 5LGr;tiapride;placebo
21 Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg) Completed NCT00001768 Phase 3 Intravenous immunoglobulin
22 Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome Recruiting NCT03066193 Phase 3 Dronabinol
23 CANNAbinoids in the Treatment of TICS (CANNA-TICS) Not yet recruiting NCT03087201 Phase 3 nabiximols;placebo
24 Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome Terminated NCT00681863 Phase 3 pramipexole 0.125 mg BID;pramipexole 0.0625 mg QD;pramipexole 0.125 mg TID;pramipexole 0.25 mg BID;pramipexole 0.0625 mg BID
25 Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome Unknown status NCT02112253 Phase 1, Phase 2
26 Cannabis for Inflammatory Bowel Disease Unknown status NCT01040910 Phase 1, Phase 2 smoking of cannabis;smoking cigarettes with placebo
27 Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder Completed NCT01904773 Phase 2 AZD5213 and placebo
28 A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome Completed NCT01647269 Phase 2
29 Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder Completed NCT01585207 Phase 1, Phase 2 vigabatrin
30 Subthalamic Stimulation in Tourette's Syndrome Completed NCT02619084 Phase 2
31 Thalamic Deep Brain Stimulation for Tourette Syndrome Completed NCT00311909 Phase 2
32 Ecopipam Treatment of Tourette Syndrome Completed NCT01244633 Phase 1, Phase 2 Ecopipam
33 VoIP Delivered Behavior Therapy for Tourette Syndrome Completed NCT02247206 Phase 2
34 Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome Completed NCT02679079 Phase 2 NBI-98854;Placebo
35 A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome Completed NCT02217007 Phase 2 SNC-102 sustained release tablet
36 N-acetylcysteine (NAC) for Children With Tourette Syndrome Completed NCT01172288 Phase 2 N-Acetylcysteine (NAC);Placebo
37 Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria Completed NCT00558467 Phase 2 pramipexole immediate release (IR);Placebo
38 Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette's Syndrome Completed NCT00529308 Phase 2
39 Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder Completed NCT00231985 Phase 2
40 Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome Completed NCT00004393 Phase 2 risperidone
41 Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome Completed NCT00004652 Phase 2 pimozide
42 Safety and Efficacy of Cannabis in Tourette Syndrome Recruiting NCT03247244 Phase 2 Cannabis;Cannabis;Cannabis
43 Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years Active, not recruiting NCT02102698 Phase 2 Ecopipam
44 Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome Active, not recruiting NCT02581865 Phase 2 NBI-98854;Placebo
45 Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome Enrolling by invitation NCT02879578 Phase 2 NBI-98854
46 FAAH Inhibitor Trial for Adults With Tourette Syndrome Suspended NCT02134080 Phase 2 PF-04457845;Placebo
47 Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome Terminated NCT01043549 Phase 2
48 Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome Terminated NCT01475383 Phase 2 PF-03654746;Placebo;Placebo;PF-03654746
49 A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette's Syndrome Withdrawn NCT01133353 Phase 2 Tetrabenazine MR;Placebo
50 A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS) Completed NCT02674321 Phase 1 SD-809

Search NIH Clinical Center for Gilles De La Tourette Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: tourette syndrome

Genetic Tests for Gilles De La Tourette Syndrome

Genetic tests related to Gilles De La Tourette Syndrome:

id Genetic test Affiliating Genes
1 Tourette Syndrome 29 24 SLITRK1

Anatomical Context for Gilles De La Tourette Syndrome

MalaCards organs/tissues related to Gilles De La Tourette Syndrome:

39
Brain, Eye, Cortex, Globus Pallidus, Thalamus, Colon, Bone

Publications for Gilles De La Tourette Syndrome

Articles related to Gilles De La Tourette Syndrome:

(show top 50) (show all 369)
id Title Authors Year
1
Cognitive flexibility and its electrophysiological correlates in Gilles de la Tourette syndrome. ( 28863370 )
2017
2
Putting the Pieces Together in Gilles de la Tourette Syndrome: Exploring the Link Between Clinical Observations and the Biological Basis of Dysfunction. ( 27783238 )
2017
3
Specific effect of a dopamine partial agonist on counterfactual learning: evidence from Gilles de la Tourette syndrome. ( 28740149 )
2017
4
Gilles de la Tourette Syndrome, Depression, Depressive Illness, and Correlates in a Child and Adolescent Population. ( 28099039 )
2017
5
A tug of war: antagonistic effective connectivity patterns over the motor cortex and the severity of motor symptoms in Gilles de la Tourette syndrome. ( 28833746 )
2017
6
Toward a Symptom-Guided Neurostimulation for Gilles de la Tourette Syndrome. ( 28289393 )
2017
7
Toward a Multifactorial Conception of the Gilles de la Tourette Syndrome and Persistent Chronic Tic Disorder. ( 28574423 )
2017
8
Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols. ( 28445405 )
2017
9
Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients. ( 28796166 )
2017
10
Gilles de la Tourette syndrome. ( 28150698 )
2017
11
Altered topology of structural brain networks in patients with Gilles de la Tourette syndrome. ( 28878322 )
2017
12
Pathological glutamatergic neurotransmission in Gilles de la Tourette syndrome. ( 28007998 )
2017
13
Gilles de la Tourette syndrome. ( 28150696 )
2017
14
Deep Brain Stimulation in Gilles de la Tourette Syndrome: What Does the Future Hold? A Cohort of 48 Patients. ( 26348012 )
2016
15
Tetrabenazine-induced oculogyric crisis - a rare complication in the treatment of Gilles de la Tourette syndrome. ( 26955276 )
2016
16
BDNF and LTP-/LTD-like plasticity of the primary motor cortex in Gilles de la Tourette syndrome. ( 27900437 )
2016
17
Temporal relationship between premonitory urges and tics in Gilles de la Tourette syndrome. ( 26922503 )
2016
18
The effects of Gilles de la Tourette syndrome and other chronic tic disorders on quality of life across the lifespan: a systematic review. ( 26880181 )
2016
19
TS-EUROTRAIN: A European-Wide Investigation and Training Network on the Etiology and Pathophysiology of Gilles de la Tourette Syndrome. ( 27601976 )
2016
20
Altered perceptual binding in Gilles de la Tourette syndrome. ( 27544346 )
2016
21
The relationship between tics, OC, ADHD and autism symptoms: A cross- disorder symptom analysis in Gilles de la Tourette syndrome patients and family-members. ( 26826899 )
2016
22
Health-related quality of life in patients with Gilles de la Tourette syndrome at the transition between adolescence and adulthood. ( 27457656 )
2016
23
New Insights into Clinical Characteristics of Gilles de la Tourette Syndrome: Findings in 1032 Patients from a Single German Center. ( 27672357 )
2016
24
Illusion of agency in patients with Gilles de la Tourette Syndrome. ( 26963083 )
2016
25
The English Version of the Gilles de la Tourette Syndrome-Quality of Life Scale for Children and Adolescents (C&A-GTS-QOL): A Validation Study in the United Kingdom. ( 27686095 )
2016
26
Impact of Perceived Stress, Anxiety-Depression and Social Support on Coping Strategies of Parents Having A Child With Gilles de la Tourette Syndrome. ( 26804511 )
2016
27
Investigation of SNP rs2060546 Immediately Upstream to NTN4 in a Danish Gilles de la Tourette Syndrome Cohort. ( 27920664 )
2016
28
Gilles de la Tourette syndrome is associated with hypermethylation of the dopamine D2 receptor gene. ( 27883923 )
2016
29
Deep brain stimulation in Gilles de la Tourette syndrome: killing several birds with one stone? ( 27746910 )
2016
30
The International Deep Brain Stimulation Registry and Database for Gilles de la Tourette Syndrome: How Does It Work? ( 27199634 )
2016
31
Aripiprazole Improves Associated Comorbid Conditions in Addition to Tics in Adult Patients with Gilles de la Tourette Syndrome. ( 27672358 )
2016
32
A preliminary examination of self-concept in older adolescents and young adults with Gilles de la Tourette syndrome. ( 28017555 )
2016
33
Health-related quality of life, anxiety and depression in parents of adolescents with Gilles de la Tourette syndrome: a controlled study. ( 27942998 )
2016
34
Cerebellar neurophysiology in Gilles de la Tourette syndrome and its role as a target for therapeutic intervention. ( 26643291 )
2015
35
Retraction Note to: Association of Catechol-O-methyltransferase val/met polymorphism with cognitive function in Gilles de la Tourette syndrome patients. ( 26282617 )
2015
36
Irritability symptoms in Gilles de la Tourette syndrome. ( 25716486 )
2015
37
Association of ADORA1 rs2228079 and ADORA2A rs5751876 Polymorphisms with Gilles de la Tourette Syndrome in the Polish Population. ( 26317759 )
2015
38
Alterations in structural connectivity may contribute both to the occurrence of tics in Gilles de la Tourette syndrome and to their subsequent control. ( 25627236 )
2015
39
The anarchic brain in action: the contribution of task-based fMRI studies to the understanding of Gilles de la Tourette syndrome. ( 26402403 )
2015
40
An fMRI investigation of motor control in Gilles de la Tourette Syndrome during imagined and executed movements. ( 26566185 )
2015
41
A t(3;9)(q25.1;q34.3) translocation leading to OLFM1 fusion transcripts in Gilles de la Tourette syndrome, OCD and ADHD. ( 25595337 )
2015
42
Gilles de la Tourette syndrome in a cohort of deaf people. ( 26216703 )
2015
43
A personal 35 year perspective on Gilles de la Tourette syndrome: assessment, investigations, and management. ( 26359615 )
2015
44
Corrections. A personal 35 year perspective on Gilles de la Tourette syndrome: assessment, investigations, and management. ( 26360068 )
2015
45
Structural Connectivity in Gilles de la Tourette Syndrome. ( 26933567 )
2015
46
Temporary deep brain stimulation in Gilles de la Tourette syndrome: A feasible approach? ( 26290773 )
2015
47
Enhanced habit formation in Gilles de la Tourette syndrome. ( 26490329 )
2015
48
Association of AADAC Deletion and Gilles de la Tourette Syndrome in a Large European Cohort. ( 26444075 )
2015
49
Premonitory Urges in Patients with Gilles de la Tourette Syndrome: An Italian Translation and a 7-Year Follow-up. ( 26288345 )
2015
50
Gilles de la Tourette syndrome is not linked to contactin-associated protein receptor 2 antibodies. ( 26462472 )
2015

Variations for Gilles De La Tourette Syndrome

ClinVar genetic disease variations for Gilles De La Tourette Syndrome:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 SLITRK1 NM_052910.2(SLITRK1): c.1264delC (p.Leu422Phefs) deletion Pathogenic rs193302861 GRCh37 Chromosome 13, 84454379: 84454379
2 SLITRK1 NM_052910.2(SLITRK1): c.*689G> A single nucleotide variant Pathogenic rs191284403 GRCh37 Chromosome 13, 84452863: 84452863
3 HDC NM_002112.3(HDC): c.951G> A (p.Trp317Ter) single nucleotide variant Pathogenic rs267606861 GRCh37 Chromosome 15, 50544717: 50544717

Copy number variations for Gilles De La Tourette Syndrome from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 60595 11 88300000 92800000 Copy number GRM5 Tourette syndrome
2 97401 16 1 7900000 Copy number A2BP1 Tourette syndrome
3 107550 17 15900000 22100000 Microdeletion Tourette syndrome
4 161233 22 17900000 22200000 Duplication COMT Tourette syndrome
5 204047 6 105500000 114600000 Copy number NKAIN2 Tourette syndrome
6 218083 7 107400000 127100000 Copy number IMMP2L Tourette syndrome
7 221370 7 143100000 147900000 Copy number CNTNAP2 Tourette syndrome
8 222485 7 152600000 155100000 Copy number DPP6 Tourette syndrome
9 257157 X 1 4300000 Deletion NLGN4 Tourette syndrome

Expression for Gilles De La Tourette Syndrome

Search GEO for disease gene expression data for Gilles De La Tourette Syndrome.

Pathways for Gilles De La Tourette Syndrome

GO Terms for Gilles De La Tourette Syndrome

Cellular components related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.56 ADRA1A ADRA2A DRD2 DRD4 DRD5 HTR3B
2 integral component of membrane GO:0016021 9.5 AADAC ADRA1A ADRA2A CNTNAP2 COMT DBH
3 axon GO:0030424 9.46 CNTNAP2 COMT DRD2 SLC6A3

Biological processes related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

(show all 33)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.96 ADRA1A COMT DRD2 SLC6A3
2 locomotory behavior GO:0007626 9.79 DBH DRD2 SLC6A3
3 learning GO:0007612 9.74 CNTNAP2 COMT DRD5
4 synapse assembly GO:0007416 9.73 BDNF DRD2 SLITRK1
5 response to cocaine GO:0042220 9.71 DRD2 DRD5 SLC6A3
6 negative regulation of adenylate cyclase activity GO:0007194 9.69 ADRA2A DRD2 DRD4
7 behavioral response to cocaine GO:0048148 9.66 DRD2 DRD4
8 response to iron ion GO:0010039 9.65 DRD2 SLC6A3
9 response to pain GO:0048265 9.65 COMT DBH
10 synaptic transmission, dopaminergic GO:0001963 9.64 DRD2 DRD5
11 transmission of nerve impulse GO:0019226 9.64 CNTNAP2 DRD5
12 negative regulation of protein secretion GO:0050709 9.63 DRD2 DRD4
13 negative regulation of cAMP biosynthetic process GO:0030818 9.63 ADRA2A DRD4
14 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.62 DRD2 DRD5
15 negative regulation of voltage-gated calcium channel activity GO:1901386 9.62 DRD2 DRD4
16 prepulse inhibition GO:0060134 9.61 DRD2 SLC6A3
17 adult behavior GO:0030534 9.61 CNTNAP2 DRD2 SLITRK1
18 striatum development GO:0021756 9.6 CNTNAP2 DRD2
19 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.59 DRD2 DRD4
20 regulation of dopamine metabolic process GO:0042053 9.58 DRD4 SLC6A3
21 adenohypophysis development GO:0021984 9.58 DRD2 SLC6A3
22 associative learning GO:0008306 9.58 DBH DRD2 DRD5
23 catecholamine biosynthetic process GO:0042423 9.55 DBH HDC
24 norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure GO:0001994 9.52 ADRA1A DRD5
25 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.5 ADRA1A ADRA2A DRD2
26 fear response GO:0042596 9.49 DBH DRD4
27 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.48 DRD2 DRD4
28 response to histamine GO:0034776 9.46 DRD2 DRD4
29 behavioral response to ethanol GO:0048149 9.43 DBH DRD2 DRD4
30 dopamine receptor signaling pathway GO:0007212 9.37 DRD2 DRD4
31 dopamine metabolic process GO:0042417 9.33 COMT DRD2 DRD4
32 dopamine catabolic process GO:0042420 9.13 COMT DBH SLC6A3
33 response to amphetamine GO:0001975 8.92 DBH DRD2 DRD4 DRD5

Molecular functions related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.65 ADRA1A ADRA2A DRD2 DRD4 DRD5
2 drug binding GO:0008144 9.54 DRD2 DRD4 SLC6A3
3 adrenergic receptor activity GO:0004935 9.33 ADRA1A ADRA2A DRD2
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.32 DRD2 DRD4
5 dopamine neurotransmitter receptor activity GO:0004952 9.13 DRD2 DRD4 DRD5
6 dopamine binding GO:0035240 8.92 DRD2 DRD4 DRD5 SLC6A3

Sources for Gilles De La Tourette Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....